The Role of Primary Tumour Location in the Selection of Biologics for the Treatment of Unresectable Metastatic Colorectal Cancer: An Endorsement of a Canadian Consensus Statement
The objective of this guideline is to make recommendations with respect to the role of primary tumour location (PTL) in the selection of epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) and vascular endothelial growth factor (VEGF) inhibitors (first-line/second-line) in addition to chemotherapy for the treatment of unresectable metastatic colorectal cancer (mCRC).
The target population consists of adult patients with RAS wild-type unresectable mCRC who are undergoing first-line or second-line chemotherapy.
Intended Guideline Users
This guideline is targeted to clinicians involved in the management of patients with mCRC.
Are there survival and/or quality of life benefits related to the selective use of EGFR monoclonal antibodies (mAbs) and VEGF inhibitors based on PTL for the first and second-line treatment of RAS wild-type, unresectable mCRC?